How should security teams govern AI systems in biological research when the model can be used for both beneficial discovery and harmful misuse?

Security teams should treat biological AI as a dual use capability and govern the full stack, not just the dataset. That means controlling model access, training inputs, outputs, and the infrastructure that runs the workflow. In practice, safeguards must account for synthetic sequence generation, prompt abuse, and downstream lab execution, because the same model can support surveillance, drug discovery, or dangerous design work.

Why biological AI needs dual use governance

Biological research models should be governed as dual use systems because the same capability can support discovery, screening, and design, while also lowering the cost of misuse. The core security task is to decide which users, workflows, and outputs are acceptable, and which combinations of access and context should be constrained, reviewed, or separated.

That means the governance target is not just the model itself. Security teams need visibility into who can invoke it, what prompts or inputs it accepts, what outputs it can produce, and whether those outputs can move into lab or automation workflows without a review step.

For teams that already govern sensitive identities and workflows, the practical lesson is to evaluate the control plane as part of the AI security stack, not as a separate policy layer after deployment. In biological use cases, separation of duties matters because a safe research environment and a misuse-resistant environment may need different permissions, logging, and approval paths.

What controls matter across the full biological AI stack?

The most effective controls sit across the full path from model access to downstream execution. Start with access control for model usage, then constrain training and retrieval inputs, apply output filtering or review for sensitive generations, and govern the infrastructure that stores artifacts or triggers tools. If the model can call systems that influence lab work, those tool paths deserve the same scrutiny as any other privileged workflow.

Biological AI also benefits from lifecycle control. Prompts, fine-tuned variants, datasets, connectors, and deployment targets change over time, so governance should include ownership, change review, and retirement. Where the model is used in a research program, teams should be able to answer who approved the capability, which version is in use, and whether the current use case still matches the original risk decision.

For teams looking to operationalize that discipline, the Agentic AI Security Policy Template is useful because it frames registration, oversight, tools, and retirement as one governance chain. The same idea applies here: if a biological model can influence downstream actions, security controls must follow the whole chain, not just the model endpoint.

At the execution layer, research teams should treat model-generated outputs as potentially actionable instructions only after policy checks. The practical difference is significant: a harmless summary, a lab-relevant recommendation, and a workflow-triggering artifact may need three different approval thresholds.

How do teams reduce misuse without blocking legitimate research?

The best balance is usually risk-tiered access. Low-risk discovery tasks can be broadly available under monitoring, while higher-risk capabilities require narrower access, stronger logging, and human review. That is usually more effective than trying to make every request look equally safe, because the harmful cases often depend on combining ordinary features in an unsafe sequence.

Monitoring should focus on intent signals, repeated probing, and unusual output patterns rather than just raw volume. Teams should also define when a request crosses from benign research assistance into a higher-risk use case, because ambiguity is where both misuse and inconsistent enforcement tend to occur. Where the model can support external execution, the review threshold should rise before the output reaches lab systems.

When biological AI is being evaluated as an enterprise capability, agentic AI threat modeling is a good mental model even if the system is not fully autonomous. The reason is simple: the governance problem is often not the generation step alone, but the chain from access, to output, to action.

Risk and Threat Considerations

Biological AI creates a dual use exposure because the same model can support legitimate discovery and lower the barrier to harmful design or operational misuse. The main risk is not merely incorrect output, but controlled output becoming operationally useful when paired with weak review, broad access, or direct lab integration.

Failure mechanism: Overly permissive access, weak output filtering, and connected tooling can let a user turn an ordinary research interaction into a misuse path, especially when generated content can be copied directly into downstream workflows.

Impact: Organizations can face unsafe experimentation, policy violations, reputational harm, or accidental enablement of higher-risk biological activity, even when the original model was deployed for beneficial research.

Standards & Framework Alignment

This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.

OWASP Agentic AI Top 10 addresses the attack surface, NIST AI RMF, NIST AI 600-1 and CSA Cloud Controls Matrix set the technical controls, and ISO/IEC 42001:2023 defines the regulatory obligations.

Framework	Control / Reference	Relevance
NIST AI RMF	GOVERN — Govern	Biological AI dual-use governance requires lifecycle oversight and accountability.
Recommendation — Establish governance, roles, and review gates for high-risk biological AI use cases.
NIST AI 600-1	GOVERN — Governance and Risk Management	GenAI controls are needed where outputs and use can support harmful misuse.
Recommendation — Apply GenAI governance to restrict sensitive use cases and review outputs before action.
ISO/IEC 42001:2023	4.2 — Needs and expectations of interested parties	AI management systems must account for stakeholders and dual-use obligations.
Recommendation — Define stakeholder expectations and control obligations for biological AI use.
OWASP Agentic AI Top 10	ASI03 — Identity & Privilege Abuse	Generated outputs may trigger privileged downstream actions in AI workflows.
Recommendation — Constrain tool access and privileged actions that can follow model output.
CSA Cloud Controls Matrix	IAM — Identity and Access Management	Controlling who can invoke research AI and related workflows is central here.
Recommendation — Limit access to biological AI systems and review privileged workflow permissions.

Practitioner Guidance

What to verify: Confirm that the model, its prompts, its outputs, and any connected workflow tools are governed as one system. If any one of those elements is outside the approval boundary, the control design is incomplete.

Decision rule: If an output could reasonably influence a lab action, require a stronger review path than you would for ordinary text generation. If the model is isolated from execution, lighter controls may be acceptable, but only when the boundary is technically enforced and logged.

What practitioners underestimate: The riskiest failure is often not a dramatic exploit, but routine research use that quietly becomes operationally actionable. The governance standard should be whether the system can be used safely at scale, not whether one test prompt looks harmless.

Practitioner takeaway: Treat biological AI as a controlled capability with bounded authority, observable outputs, and explicit human decision points wherever generated content can cross into real-world execution.